Upcoming Events
Nordic Life Science Days 2026
Sep 8th - 9th, 2026
Stockholm, Sweden
Kistamässan
Meet MMS Holdings at Nordic Life Science Days 2026 to discuss regulatory, biometrics, and clinical development solutions.
SCDM Annual Conference 2026
Sep 14th - 17th, 2026
Raleigh, North Carolina, USA
Raleigh Convention Center
Meet MMS Holdings at SCDM 2026 to discuss clinical data management, biostatistics, and data science innovation.
RAPS Convergence 2026
Sep 15th - 17th, 2026
Charlotte, North Carolina, USA
Charlotte Convention Center
Meet MMS Holdings at RAPS Convergence 2026 to discuss global regulatory strategy, compliance, and clinical development
Suggested For You
perspectives
September 3rd, 2026
From Signal to System: FDA Approval Does Not Mean Treatment Can Begin the Next Morning
perspectives
August 27th, 2026
Risk-Based Data Management: Moving Beyond Traditional Data Cleaning
perspectives
August 17th, 2026
From Signal to System: The Evidence Questions Psychedelic Therapies Must Answer
webinar
September 10th, 2026
The Evolution of REMS: FDA Risk Management Considerations for Novel Risks Associated with Psychoactive Drugs
perspectives
August 11th, 2026
The Race to Faster Drug Development: A Quicker On-Ramp Doesn’t Help If You’re Headed the Wrong Way
perspectives
August 7th, 2026
UK Clinical Trial Transparency Changes for Phase I Studies: What Sponsors Need to Know
case study
July 31st, 2026
Delivering Strategic Biostatistics Support to Enable Phase 2b Funding Decisions
perspectives
July 31st, 2026
FDA Orphan Drug Designation Requirements: Key Mistakes to Avoid
perspectives
July 29th, 2026
From Signal to System: The Next Challenges for Psychedelic Therapies
webinar
August 20th, 2026
Risk-Based Data Management: Success Factors, Risks, and What Comes Next
perspectives
July 24th, 2026
FDA’s Latest Psychedelic Guidance: Key Changes and Implications for Sponsors
whitepaper
July 23rd, 2026
Lessons from Outside Pharma for Faster, More Usable Data